Tumours of the breast are often hormone-dependent, meaning their growth is driven by steroid hormones such as estrogen. This hormone acts upon the estrogen receptor (ER), which together with other transcription factors such as FOXA1 drives tumour growth.
Centre for Cancer Research and Cell Biology
Dr E Kerr, Dr I Mills
30 January 2019
Mutant KRAS driven metabolic reprogramming is a key hallmark of cancer, providing the building blocks necessary to support aberrant cancer cell proliferation and is often achieved through rewiring glycolytic, mitochondrial and fatty acid metabolism, reportedly leading to mitochondrial dysfunction.